Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast

The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly), have been central to the treatment of advanced disease, the market is expected to undergo a significant shift over the next 10 years. This shift will be driven by the approvals of Tecentriq (Roche / Genentech) plus bevacizumab and of Imfinzi plus Imjudo (AstraZeneca / MedImmune); the FDA’s accelerated approval of Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical); and the anticipated entry of novel immune checkpoint inhibitor-based combinations. The expected uptake of these premium-priced regimens and their label expansion to the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma therapy market, in which unmet needs remain to offer further opportunities for growth.

Questions answered

  • What is the size of the market-relevant drug-treatable populations, and how will drug-treatment rates change over time?
  • What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?
  • What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts’ insights on key existing and emerging therapies?
  • What are the key factors driving or constraining market growth?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports